SI Material and Methods
Identification of Genetic Findings. All samples were sequenced on the Illumina HiSeq X sequencer following standard validation protocols. Reads were mapped to human reference hg38 using ISIS analysis software. A depth of 30-50 reads was achieved for 93% of the reference genome (1). Genetic variants were annotated using integrated public and proprietary annotation sources, including ClinVar, HGMD Professional, OMIM and RefSeq (2) , (3) . We used an internal version of HLI Search in a two-step process: the first step focused on minor allele frequency (MAF) <1% in the HLI cohort (~16,000 WGS) with an annotation of pathogenic (P), likely pathogenic (LP), or a variant of unknown significance (VUS) using ClinVar or disease mutations (DM) using HGMD Professional as well as predicted loss-of-function variants, nonsense, frameshift, canonical splice site (+/-1 to 2 bp), of protein-coding genes. A second query of the patients' whole genome sequencing data was targeted to reported disease causative genes/variants where phenotypes collected through our full range of tests suggested a genetic basis for disease.
We developed disease-specific panels, using ClinVar, HGMD, HPO, and OMIM databases (2), (3), (4), based on participants suspected genetic disorders. Our two-step process evaluates variants in 30,281 unique genes, collectively present in ClinVar, HGMD, and OMIM. Common pathogenic variants or risk alleles with allele frequency >1%, including the CFTR p.Phe508del, GJB2 p.Met34Thr, CYP21A2 p.Val282Leu, SERPINA1 p.Glu366Lys and p.Glu288Val, F2 c.*97G>A, FLG p.Ser761fs and p.Arg501*, F5 p.Arg534Gln, G6PD p.Val68Met, BTD p.Asp446His, ALDH2 p.Glu504Lys, and HFE p.Cys282Tyr were also included.
Genetic variants were manually interpreted using ACMG guidelines (5) . We evaluated evidence in categories, including population data, computational data, functional data, segregation data, for sequence variants and used the rules for combining criteria to classify sequence variants for pathogenicity. For this study, two independent pairs of clinical geneticists and research scientists interpreted genetic variants, reviewed genetic variants and integrated genetic results with corresponding deep phenotypic data reviewed by a multidisciplinary team, including a cardiologist, a neurologist, radiologists, primary care physicians, and registered nurses per study participant. Clinical presentations listed in OMIM clinical synopses or in publications such as GeneReviews or primary studies were employed to evaluate genotype and phenotype associations. The multidisciplinary team discussed and evaluated if it was reasonable to report a variant of uncertain significance, denoted as VUS-R, based on each study participants' genotype and phenotype data.
Metabolomics
The non-targeted metabolomics analysis of 1,007 metabolites was performed at Metabolon, Inc. (Durham, North Carolina, USA) on a platform consisting of four independent ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods. The detailed descriptions of the platform can be found in our previous publications (6) . Blood plasma was used for analysis, and values from multiple experimental batches were normalized into Z-scores based on a reference cohort of either 42 (n=457) or 300 (n=176) self-reported healthy individuals run with each batch. The 42 and 300-normalized batches were converted to the same scale using linear transformation based on the values obtained from 7 runs that included both the 42 and 300 controls.
Samples with metabolite measurements that were below the detection threshold were imputed as the minimum value for that metabolite. Other missing metabolite levels were imputed using the missForest R package. Clinical tests such as quantose impaired glucose tolerance (IGT) test (7) , and insulin resistance (IR) test (8) were also performed at Metabolon, Inc. IR, IGT, and non-targeted metabolomic tests are all measured after at least 8 hours of fasting. Participants were advised to avoid taking supplements or over-thecounter medications.
For the genomics and metabolomics association for the extreme metabolites (±6 S.D.), rare functional genetic variants are identified using four criteria: 1) annotated as pathogenic in ClinVar, 2) annotated as disease mutation (DM) in HGMD or variant of unknown significance in ClinVar with minor allele frequency (MAF) <0.025, 3) annotated as a gene coding region with MAF <0.01 CADD>15, or 4) annotated as a gene noncoding region with a CDTS score <0.01 and MAF <0.01 (9) . Variants are in heterozygous state unless noted.
Gene-Base Collapsing Analysis
We performed a gene-based collapsing analysis to identify genes where carrying a rare functional variant was associated with increased or decreased metabolite levels relative to non-carriers. For this purpose, "rare functional variant" was defined as having a minor allele frequency (MAF) <0.5%, a CADD score>15, and being annotated as coding. These carrier statuses for each gene were used as the "genotypes" in genetic association analyses.
A genetic similarity matrix (GSM) was constructed from ~300,000 variants that represented a random 20% of all common (MAF >5%) variants genome-wide after linkagedisequilibrium (LD) pruning (r2 less than 0.6, window size 200 kb) and was used to model the random effect in the linear mixed model via a "leave-out-one-chromosome" method for each tested variant. Each gene was tested independently using customized Python scripts wrapping the FaST-LMM package (10) . Analyses were performed both in all participants and separately in European ancestry participants only. The phenotypes analyzed were the levels of each metabolite, which were rank-ordered and forced to a normal distribution within each cohort before being combined for the genetic analysis. Statistically significant associations were identified using Bonferroni correction for multiple tests. Test statistic inflation was assessed with QQ plots.
Non-Contrast Whole-Body MRI. MRIs were interpreted by three board-certified radiologists. Quantitative post-processing for volumetric brain imaging (Neuroquant, CorTechs Labs), brain white-matter assessment, whole body detection of solid tumors with diffusion-weighted imaging(11) , (12) , neurological and cardiovascular assessment, cardiac structure and function, liver-specific fat and iron estimation, and body compartmentspecific fat and muscle (Advanced MR AnalyticsAB) were used and details are listed in Table S1 . 
TwinsUK Study Cohort
To expand our sample set for analyses, we also included metabolome data from 1,969
European ancestry twins enrolled in the TwinsUK registry, a British national register of adult twins (13) . We previously reported a detailed study of the genetic variants influencing the human metabolome in this cohort (6) . For the present study, we used data from serum samples that were collected at the first of three visits, when the participant's age ranged from 33 to 74 years old (median 51). The cohort is mainly composed of females (96.7%), and the sample set we used included 388 monozygotic twin pairs, 519 dizygotic twin pairs, and 155 unrelated individuals. Similar to the Health Nucleus cohort, the non-targeted metabolomics analysis of 1011 metabolites was performed at Metabolon, Inc. For this cohort, blood serum was used for analysis, and the resulting raw values were transformed to z scores using the mean and standard deviation. Modified PIRADS evaluation for cancer detection DWI: diffusion weighted imaging; FLAIR: fluid-attenuated inversion recovery; FSE: fast spin echo; FSPGR: fast spoiled gradient echo; GRE: gradient echo; HASTE: half Fourier single-shot turbo spin echo; MPRAGE: magnetization-prepared 180 degrees radiofrequency pulses and rapid gradient-echo; MRA: magnetic resonance angiography; NSA: number of signal averages; PIRADS: prostate imaging reporting and data system; RSI: restriction spectrum imaging; SSFSE: single shot fast spin echo; TSE: turbo spin echo. 
ABHD14A-ACY1
Aminoacylase 1 deficiency 7.7E-23 1.1E-17 ↑ N-acetylalanine 0.68%
Aminoacylase 1 deficiency 2.2E-22 3.8E-18 ↑ N-acetylmethionine 0.68%
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